Tonix Pharmaceuticals Holding Corp.
TNXP · XNASCIK 1430306fmd_02PQCZ97VDV2HFJRKP45QG5ES9制造业 · 医药制剂模板: 标准
覆盖范围: 2008年1月01日 至 2026年9月30日，共 69 个期间
| 项目 | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| 营业总收入 | – | – | – | – | – | – | – | 8 | 10 | 13 |
| 净利息收入 | – | – | – | – | – | – | – | – | – | – |
| 营业成本 | – | – | – | – | – | – | – | 5 | 8 | 7 |
| 毛利润 | – | – | – | – | – | – | – | 3 | 2 | 6 |
| 信用损失准备 | – | – | – | – | – | – | – | – | – | 0 |
| 研发费用 | 29 | 13 | 18 | 18 | 36 | 69 | 82 | 87 | 40 | 44 |
| 销售、一般及管理费用 | – | – | – | – | – | – | 30 | 35 | 40 | 88 |
| 营业费用合计 | – | – | – | – | – | – | – | – | – | – |
| 营业利润 | (39) | (21) | (26) | (29) | (51) | (92) | (112) | (118) | (137) | (126) |
| 利息费用 | – | – | – | – | – | – | – | – | 1 | 0 |
| 利息及投资收益 | 0 | 0 | 0 | 0 | 0 | 0 | 2 | 2 | 0 | 4 |
| 其他营业外收入（支出） | – | – | – | – | – | – | – | 2 | (1) | (3) |
| 税前利润 | (39) | (21) | (26) | (29) | (50) | (92) | (110) | (117) | (130) | (124) |
| 净利润 | (39) | (21) | (26) | (29) | (50) | (92) | (110) | (117) | (130) | (124) |
| 归属于普通股股东的净利润 | – | (21) | (29) | (31) | (52) | (92) | (117) | (117) | (130) | (124) |